Table 8.
Subgroup | Number of studies | Pooled HR (95%CI) | Heterogeneity |
---|---|---|---|
OS | |||
Origin of ctDNA | |||
Serum | 2 | 3.07(1.51,6.25) | I2 = 0.0%, p = 0.947 |
Plasma | 3 | 2.78(1.40, 5.53) | I2 = 71.9%,p = 0.029 |
FIGO stage | |||
III/IV | 3 | 3.37(2.15, 5.28) | I2 = 15.9%,p = 0.305 |
I-IV | 2 | 1.82(1.24, 2.68) | I2 = 16.6%, p = 0.274 |
Detection methods | |||
Real time-PCR | 4 | 2.16(1.60, 2.93) | I2 = 8.7%,p = 0.350 |
Digital PCR | 1 | 7.29(2.46, 21.59) | / |
PFS | |||
Origin of ctDNA | |||
Serum | 1 | 3.0 (1.44, 6.48) | / |
Plasma | 4 | 2.41 (1.70, 3.42) | I2 = 25.9%,p = 0.256 |
FIGO stage | |||
III/IV | 3 | 3.41(2.03, 5.72) | I2 = 0.0%, p = 0.426 |
I-IV | 2 | 2.10(1.41, 3.13) | I2 = 0.0%, p = 0.456 |
Detection methods | |||
Real time-PCR | 3 | 2.28(1.60, 3.24) | I2 = 0%, p = 0.524 |
Digital PCR | 2 | 3.76(1.84, 7.69) | I2 = 35.5%, p = 0.213 |